病例分享:糖尿病肾病合并高血压的诊治

2023-04-14 网络 网络 发表于上海

"高血压"病史6年余,血压最高达160/100mmHg,现规律口服"厄贝沙坦片0.15g日1"现血压控制尚可。

· 详细病史

一般资料:

性别:女

年龄:56

文化程度:小学

婚否:已婚

主诉:主因“头晕头沉5年余,再发加重2天”门诊治疗

现病史:患者于入院5年前始无明显诱因出现头晕头沉,无恶心呕吐,无咳嗽咳痰,无腹痛腹泻,无视物旋转及视物模糊,无言语不利及肢体活动障碍,休息数小时后症状可缓解,但反复发作。曾因症状加重就诊于我院,完善相关检查后,诊断椎基底动脉供血不足。家中间断口服盐酸氟桂利嗪等药物治疗,症状偶有发作。2天前始无明显诱因头晕再发,性质同前,口服上述药物效果欠佳,现为求进一步治疗就诊于我院门诊。

既往史:"高血压"病史6年余,血压最高达160/100mmHg,现规律口服"厄贝沙坦片0.15g日1"现血压控制尚可。"2型糖尿病"病史6年余,现规律口服"达格列净片,长秀霖胰岛素皮下注射"治疗,现血糖控制可。"肾病综合征"病史6年余,曾口服中药治疗,现已停药2年余。

过敏史:无

婚育史:24岁结婚,育有2女,爱人及女儿均体健。

个人史:生于原籍并久居此地,未到过疫区及牧区,无放射性物质接触史,无吸烟饮酒史。

家族史:否认家族性遗传病及传染病史。

· 临床检查选填

体格检查 发育正常,营养中等,正立体型,

专科检查:

实验室检查:

填写主要阳性结果及相关有意义阴性结果:

影像学检查:

填写主要阳性结果及相关有意义阴性结果,并附上相应图片或视频

· 检查结果选填,若填写请将患者有关信息进行脱敏处理

实验室化验单和/或影像学(超声、CT、核磁等)/电生理学检查(脑电图)图片粘贴处:

 

· 诊断及鉴别诊断(必填)

椎基底动脉供血不足 高血压病2级 极高危 2型糖尿病 肾病综合征

· 治疗经过/治疗决策(必填)

· 拜阿司匹林肠溶片100mg 1/日,阿托伐他汀钙片20mg 1/日,厄贝沙坦片150mg1/日,达格列净10mg 1/日,养血清脑颗粒4g 3/日

· 随访及预后(必填)

无头晕头沉,血压控制在130/80mmHg,空腹血糖控制在5.0到7.0之前

小结:

根据《2013ESHESC高血压治疗指南》糖尿病一旦合并高血压即为极高危或很高危,极易造成靶器官损害或并发疾病1。安博维是唯一具有糖尿病肾病适应症的降压药2,能够更好的为高血压病人提供肾保护,延缓疾病发展。

 

特别说明:

1. 为了保护患者隐私,请删除病例中的患者真实姓名、住址、医保卡号、联系电话等个人信息。

2.本次活动所获得的个人信息,如联系方式、地址等,我们承诺将严格保密。

 

1. 2013ESHESC高血压治疗指南

2.安博维产品说明书

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2138811, encodeId=e691213881114, content=认真学习专业, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1bf8711703, createdName=ms1000000739434148, createdTime=Wed May 24 13:50:03 CST 2023, time=2023-05-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2126036, encodeId=452e21260365c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Sat Apr 15 07:27:35 CST 2023, time=2023-04-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2125993, encodeId=fb00212599326, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Fri Apr 14 23:24:58 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2125982, encodeId=cf122125982d6, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 14 21:55:37 CST 2023, time=2023-04-14, status=1, ipAttribution=山西省)]
    2023-05-24 ms1000000739434148 来自江西省

    认真学习专业

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2138811, encodeId=e691213881114, content=认真学习专业, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1bf8711703, createdName=ms1000000739434148, createdTime=Wed May 24 13:50:03 CST 2023, time=2023-05-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2126036, encodeId=452e21260365c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Sat Apr 15 07:27:35 CST 2023, time=2023-04-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2125993, encodeId=fb00212599326, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Fri Apr 14 23:24:58 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2125982, encodeId=cf122125982d6, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 14 21:55:37 CST 2023, time=2023-04-14, status=1, ipAttribution=山西省)]
    2023-04-15 ms2000000702445417 来自云南省

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2138811, encodeId=e691213881114, content=认真学习专业, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1bf8711703, createdName=ms1000000739434148, createdTime=Wed May 24 13:50:03 CST 2023, time=2023-05-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2126036, encodeId=452e21260365c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Sat Apr 15 07:27:35 CST 2023, time=2023-04-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2125993, encodeId=fb00212599326, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Fri Apr 14 23:24:58 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2125982, encodeId=cf122125982d6, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 14 21:55:37 CST 2023, time=2023-04-14, status=1, ipAttribution=山西省)]
    2023-04-14 1013100771 来自山东省

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2138811, encodeId=e691213881114, content=认真学习专业, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1bf8711703, createdName=ms1000000739434148, createdTime=Wed May 24 13:50:03 CST 2023, time=2023-05-24, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2126036, encodeId=452e21260365c, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940a5479132, createdName=ms2000000702445417, createdTime=Sat Apr 15 07:27:35 CST 2023, time=2023-04-15, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2125993, encodeId=fb00212599326, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d114843943, createdName=1013100771, createdTime=Fri Apr 14 23:24:58 CST 2023, time=2023-04-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2125982, encodeId=cf122125982d6, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Apr 14 21:55:37 CST 2023, time=2023-04-14, status=1, ipAttribution=山西省)]
    2023-04-14 医鸣惊人 来自山西省

    认真学习了

    0

相关资讯

王继光教授|高血压合并糖尿病肾病,如何选择降压治疗策略?

高血压既是糖尿病肾病的主要合并症,也是其重要的危险因素之一,而糖尿病肾病还可导致高血压的危害进一步加重。

高血压撞上糖尿病,如何应对倍增的甜蜜负担

我国高血压的患病率呈现出逐年增高的趋势。实际上,作为心脑血管病的危险因素,高血压往往不是单独存在的。

病例分享:高伴糖患者的血压治疗心得

二氢吡啶类CCB和ARB都是很常用的降压药物,广泛应用于临床,高血压患者往往同时合并多种病症,尤其是当合并糖尿病时,要同时考虑到两种疾病的特性选择更适合患者的治疗方案。

高血压合并糖尿病,如何兼顾降压疗效及靶器官保护

糖尿病和高血压是两种高发的严重危害健康的疾病,两者常共存。对糖尿病患者进行有效的血压管理,保护靶器官,对于预防和延缓糖尿病并发症、降低糖尿病和高血压的疾病负担具有重要意义。

从高血压合并CKD患者的需求出发,合理解读降压药物经济学研究

2022年4月,Front. Pharmacol.杂志发表了一项中国大型回顾性队列研究,比较原研和仿制降压药的临床结局和医疗成本.

优化非糖尿病CKD患者的抗高血压治疗

非糖尿病肾病抗高血压文献综述。